Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Purerfellner, H; Derndorfer, M; Anelli-Monti, B; Strohmer, B; Rotman, B; Roithinger, FX; Martinek, M.
Clinical Results with Dronedarone (MULTAQ) in non-permanent Atrial Fibrillation - Results of the DEMETER Registry
J KARDIOL. 2015; 22:
Web of Science


Autor/innen der Med Uni Graz:
Rotman Brigitte

Introduction: Dronedarone (Multaq(R), Sanofi) is a multi-channel blocker used for drug therapy in non-permanent atrial fibrillation (AF). In Austria this antiarrhythmic agent is available since 02/2010. We report the clinical results of the prospective DEMETER registry (02/2010-12/2011). Methods: Six Austrian hospitals added 94 patients to the study (ambulatory or stationary). Inclusion criteria were first time AF (2.2%), paroxysmal AF (72.3%), persistent AF (24.4%) and longstanding persistent AF (1.1%). ECG parameters (rhythm, heart rate, PR, QTc), laboratory findings (renal and hepatic parameters), NYHA stages, CHADS2 scores and echocardiographic data (LVEF and atrial diameters) were recorded at baseline (BL) and reevaluated after 3 and 6 month including quality of life (QoL) concerning AF. Results: 55% of all patients were able to complete the study compliant to the protocol, 20% were lost to follow-up and discontinuation was documented in 15% of pts. Recurrent AF was the main reason for termination (75%). Proarrhythmic effects or deaths were not observed. Rehospitalisation rate was low (8.3%) and limited to recurrent AF. Over a period of 6 month there was no relevant progression of sinus rhythm (SR) into persistent AF, liver and renal function remained stable. Relevant changes in ECG parameters could not be observed, NYHA stages decreased from visit to visit and patients expressed a significant better QoL right from the first follow-up (FU1). Conclusions: Concerning symptoms, ECG, renal and hepatic parameters, Dronedarone seems to be safe and well tolerated with infrequent side effects, significantly decreasing clinical heart failure (p = 0.0001) and improving QoL (p = 0.013) in hemodynamically stable patients suffering from non-permanent AF. A high lost to follow-up proportion of 45% limits the explanatory power of the registry.

Find related publications in this database (Keywords)
atrial fibrillation
Multaq (R)
© Meduni Graz Impressum